InvestSMART

Alterity Therapeutics Limited (ASX: ATH) - Announcements

Current share price for ATH : $0.560 0.015 (2.61%)+

ASX company news and announcements for Alterity Therapeutics Limited (ATH) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Alterity Therapeutics Limited (ATH) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Alterity Therapeutics Limited (ATH), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Alterity Therapeutics Limited (ATH)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$122 Proposed issue of securities - ATH 18 Jul 2024 12:16PM $0.005 $0.560 risen by 12,344.44%
$122 Positive Interim Data from ATH434-202 Phase 2 Clinical Trial 17 Jul 2024 10:20AM $0.005 $0.560 risen by 11,100%
$122 Trading Halt 15 Jul 2024 9:25AM $0.005 $0.560 risen by 11,100%
$122 Notification regarding unquoted securities - ATH 28 Jun 2024 4:58PM $0.004 $0.560 risen by 13,900%
$122 Alterity to Present at Hidden Gems in Life Sciences Webinar 13 Jun 2024 8:42AM $0.004 $0.560 risen by 13,900%
$122 Webcast Today - New Data from bioMUSE Natural History Study 30 May 2024 8:39AM $0.005 $0.560 risen by 11,100%
$122 Notification of cessation of securities - ATH 21 May 2024 3:19PM $0.005 $0.560 risen by 11,100%
$122 Phase 2 DMC Recommends Continuing Clinical Trial as Planned 8 May 2024 8:27AM $0.006 $0.560 risen by 9,233.33%
$122 Ceasing to be a substantial holder 8 May 2024 8:20AM $0.006 $0.560 risen by 9,233.33%
$122 Change in substantial holding 3 May 2024 8:23AM $0.006 $0.560 risen by 9,233.33%
$122 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2024 9:06AM $0.006 $0.560 risen by 9,233.33%
$122 Application for quotation of securities - ATH 29 Apr 2024 9:01AM $0.006 $0.560 risen by 9,233.33%
$122 Alterity Presents New Data on ATH434 29 Apr 2024 8:41AM $0.006 $0.560 risen by 9,233.33%
$122 Change in substantial holding 18 Apr 2024 8:24AM $0.005 $0.560 risen by 11,100%
$122 Alterity Parkinson's and MSA Data Featured at AAN Meeting 17 Apr 2024 8:48AM $0.005 $0.560 risen by 11,100%
$122 Application for quotation of securities - ATH 15 Apr 2024 10:40AM $0.008 $0.560 risen by 7,366.67%
$122 Options Prospectus 12 Apr 2024 11:30AM $0.007 $0.560 risen by 8,515.38%
$122 Results of Extraordinary General Meeting 12 Apr 2024 10:47AM $0.006 $0.560 risen by 9,233.33%
$122 Alterity to Present New ATH434 Data at Orphan Drug Congress 10 Apr 2024 8:35AM $0.005 $0.560 risen by 11,100%
$122 Alterity Receives a $3.9 million R&D Tax Incentive Refund 26 Mar 2024 1:15PM $0.005 $0.560 risen by 12,344.44%
$122 Change in substantial holding 25 Mar 2024 8:21AM $0.005 $0.560 risen by 12,344.44%
$122 Notice of Extraordinary General Meeting/Proxy Form 14 Mar 2024 9:08AM $0.004 $0.560 risen by 13,900%
$122 Becoming a substantial holder 7 Mar 2024 8:15AM $0.004 $0.560 risen by 13,900%
$122 Change in substantial holding 6 Mar 2024 8:18AM $0.004 $0.560 risen by 13,900%
$122 Notice Under Section 708A 4 Mar 2024 10:34AM $0.004 $0.560 risen by 13,900%

176 - 200 of 549 results

Page 8 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.